HomeBUSINESS
BUSINESS

Novartis to Keep Close Eye on Discussions on Clozaril at Chuikyo, Expects Strengthened Measures to Promote Proper Use
(Nov.30.2017)

Yoshitaka Kato, head of neuro science business
As a key health ministry panel has begun discussing measures to promote the use of Novartis Pharma’s schizophrenia treatment Clozaril (clozapine), Novartis will keep a close eye on the course of the discussions while preparing to take necessary measures to ensure the product’s proper use, a company official said in a recent interview with Jiho ...
(LOG IN FOR FULL STORY)

News Calendar